146 related articles for article (PubMed ID: 8181193)
1. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population.
May DG; Porter J; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1994 May; 55(5):492-500. PubMed ID: 8181193
[TBL] [Abstract][Full Text] [Related]
2. Activity of oxidative routes of metabolism of debrisoquin, mephenytoin, and dapsone is unrelated to the pathogenesis of vinyl chloride-induced disease.
Black C; May G; Csuka ME; Lupoli S; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1992 Dec; 52(6):659-67. PubMed ID: 1458774
[TBL] [Abstract][Full Text] [Related]
3. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
May DG; Black CM; Olsen NJ; Csuka ME; Tanner SB; Bellino L; Porter JA; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1990 Sep; 48(3):286-95. PubMed ID: 2401127
[TBL] [Abstract][Full Text] [Related]
4. Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole.
Caraco Y; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Oct; 60(4):396-404. PubMed ID: 8873687
[TBL] [Abstract][Full Text] [Related]
5. Dapsone N-acetylation, metoprolol alpha-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial.
Setiabudy R; Kusaka M; Chiba K; Darmansjah I; Ishizaki T
Clin Pharmacol Ther; 1994 Aug; 56(2):142-53. PubMed ID: 8062490
[TBL] [Abstract][Full Text] [Related]
6. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects.
Frye RF; Branch RA
Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639
[TBL] [Abstract][Full Text] [Related]
7. The disposition of dapsone in cirrhosis.
May DG; Arns PA; Richards WO; Porter J; Ryder D; Fleming CM; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1992 Jun; 51(6):689-700. PubMed ID: 1611807
[TBL] [Abstract][Full Text] [Related]
8. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
Sanz EJ; Villén T; Alm C; Bertilsson L
Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
[TBL] [Abstract][Full Text] [Related]
9. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.
Dahl ML; Tybring G; Elwin CE; Alm C; Andreasson K; Gyllenpalm M; Bertilsson L
Clin Pharmacol Ther; 1994 Aug; 56(2):176-83. PubMed ID: 8062494
[TBL] [Abstract][Full Text] [Related]
11. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors.
Kaisary A; Smith P; Jaczq E; McAllister CB; Wilkinson GR; Ray WA; Branch RA
Cancer Res; 1987 Oct; 47(20):5488-93. PubMed ID: 3652049
[TBL] [Abstract][Full Text] [Related]
12. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
[TBL] [Abstract][Full Text] [Related]
13. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
[TBL] [Abstract][Full Text] [Related]
14. Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agents.
LLerena A; Herraíz AG; Cobaleda J; Johansson I; Dahl ML
Clin Pharmacol Ther; 1993 Dec; 54(6):606-11. PubMed ID: 7903915
[TBL] [Abstract][Full Text] [Related]
15. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.
Frye RF; Matzke GR; Adedoyin A; Porter JA; Branch RA
Clin Pharmacol Ther; 1997 Oct; 62(4):365-76. PubMed ID: 9357387
[TBL] [Abstract][Full Text] [Related]
16. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
[TBL] [Abstract][Full Text] [Related]
17. Reproducibility over time of mephenytoin and debrisoquine hydroxylation phenotypes.
Llerena A; Valdivielso MJ; Benítez J; Bertilsson L
Pharmacol Toxicol; 1993 Jul; 73(1):46-8. PubMed ID: 8234192
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic characteristics of the eosinophilia-myalgia syndrome.
Flockhart DA; Clauw DJ; Sale EB; Hewett J; Woosley RL
Clin Pharmacol Ther; 1994 Oct; 56(4):398-405. PubMed ID: 7955801
[TBL] [Abstract][Full Text] [Related]
19. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
20. In vivo modulation of CYP enzymes by quinidine and rifampin.
Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
